Patient Assistance & Copay Programs for Fulyzaq Patient assistance programs (PAPs) are usually sponsored by pharmaceutical companies and provide free or discounted medicines and copay programs to low income or uninsured and under-insured people who meet specific guidelines. Eligibility requirements vary for each program.
Full Answer
What is Fulyzaq used to treat?
FULYZAQ is indicated for symptomatic relief of non-infectious diarrhea in patients with HIV/AIDS on anti-retroviral therapy. The recommended dose of FULYZAQ is one 125 mg delayed-release tablet taken orally two times a day, with or without food. Fulyzaq Tablets should not be crushed or chewed. Tablets should be swallowed whole.
How do you take Fulyzaq for diarrhea?
FULYZAQ is indicated for symptomatic relief of non-infectious diarrhea in patients with HIV/AIDS on anti-retroviral therapy. The recommended dose of FULYZAQ is one 125 mg delayed-release tablet taken orally two times a day, with or without food.
What is the recommended dose of Fulyzaq?
The recommended dose of FULYZAQ is one 125 mg delayed-release tablet taken orally two times a day, with or without food. Fulyzaq Tablets should not be crushed or chewed. Tablets should be swallowed whole. FULYZAQ is a white, oval, enteric-coated 125 mg delayed-release tablet printed on one side with 125SLXP. None.
What is the cost of Fulyzaq oral delayed release?
The cost for Fulyzaq oral delayed release tablet 125 mg is around $628 for a supply of 60 tablets, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans.
What is FULYZAQ used for?
FULYZAQ is indicated for symptomatic relief of non-infectious diarrhea in patients with HIV/AIDS on anti-retroviral therapy.
Where is fulyzaq extracted from?
The botanical drug substance of FULYZAQ is extracted from Croton lechleri (the botanical raw material) that is harvested from the wild in South America.
Is FULYZAQ based on a presumptive diagnosis of non-infectious diarrhea?
If infectious etiologies are not considered, and FULYZAQ is initiated based on a presumptive diagnosis of non -infectious diarrhea, then there is a risk that patients with infectious etiologies will not receive the appropriate treatments, and their disease may worsen. Before starting FULYZAQ, rule out infectious etiologies of diarrhea. FULYZAQ is not indicated for the treatment of infectious diarrhea.
Is there an overdose on Crofelemer?
There has been no reported experience with overdosage of crofelemer.
Does FULYZAQ interact with zidovudine?
FULYZAQ administration did not have a clinically relevant interaction with nelfinavir, zidovudine, or lamivudine in a drug-drug interaction trial.
Can NiceRx help me get Fulyzaq if I have insurance?
We may even be able to help if you don’t have insurance .
Does NiceRx provide Fulyzaq coupons?
We do not provide Fulyzaq coupons, Fulyzaq discount cards or Fulyzaq copay cards. We don’t offer printable Fulyzaq manufacturer coupons, Fulyzaq discounts, rebates, Fulyzaq savings cards, trial offers, or free Fulyzaq samples. We are a service provider that helps eligible individuals access the Fulyzaq patient assistance program. If you’re looking for coupons for Fulyzaq or cheap Fulyzaq, keep in mind you can likely save more with NiceRx. When obtaining your Fulyzaq medication through NiceRx, you will only pay $49 per month for each medication.
How to contact Xifaxan?from xifaxan.com
Patients who need assistance with their monthly copays can call 1-866-XIFAXAN ( 1-866-943-2926 ).
What is Xifaxan 550 mg?from xifaxan.com
XIFAXAN ® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
What is Salix Pharmaceuticals?from patientassistance.com
Salix Pharmaceuticals is a company focused on gastrointestinal diseases . Salix has a special search and development team, dedicated to the discovery of drugs which are already in the late stages of development, or are otherwise currently in the marketplace. Salix ensures that their products have acquired great responses in their studies for safety and efficacy. Working hard to maximize the commercialization of their products, Salix outsources the manufacturing of their products to result in cost effective drugs for their clientèle.
What is Salix committed to?from salix.com
At Salix, we are committed to giving people more than just treatments —we provide access, support, and helpful information.
How to report a drug reaction to Salix?from xifaxan.com
To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Is Xifaxan contraindicated?from xifaxan.com
XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
Is Xifaxan covered by Medicare?from xifaxan.com
Double-check coverage; Medicare excludes certain kinds of drugs, but XIFAXAN is not in those categories. Medication not covered. You can ask insurance plan to reevaluate; XIFAXAN is covered for 99% of commercially insured patients and 95% of Medicare patients 1†§. † Salix Pharmaceuticals does not guarantee coverage or reimbursement for the product.
What is Salix Pharmaceuticals?from patientassistance.com
Salix Pharmaceuticals is a company focused on gastrointestinal diseases . Salix has a special search and development team, dedicated to the discovery of drugs which are already in the late stages of development, or are otherwise currently in the marketplace. Salix ensures that their products have acquired great responses in their studies for safety and efficacy. Working hard to maximize the commercialization of their products, Salix outsources the manufacturing of their products to result in cost effective drugs for their clientèle.
What is Salix committed to?from salix.com
At Salix, we are committed to giving people more than just treatments —we provide access, support, and helpful information.
How many Americans can't afford medication?from patientassistance.com
There are over 100 million Americans that either can‚t afford their medication or are struggling to afford their medication. We aim to help each and every American in that situation.
Does Salix Pharmaceuticals offer patient assistance?from patientassistance.com
Salix Pharmaceuticals Patient Assistance Program, a patient assistance program provided by Salix Pharmaceuticals, offers a year’s supply of the medications listed to the right at no cost to those who are eligible for the program. Eligibility is based off of the following requirements:
Indications and Usage
Dosage and Administration
- The recommended dose of FULYZAQ is one 125 mg delayed-release tablet taken orally two times a day, with or without food. Fulyzaq Tablets should not be crushed or chewed. Tablets should be swallowed whole.
Dosage Forms and Strengths
- FULYZAQ is a white, oval, enteric-coated 125 mg delayed-release tablet printed on one side with 125SLXP.
Warnings and Precautions
- 5. 1 Risks of Treatment in Patients with Infectious Diarrhea
If infectious etiologies are not considered, and FULYZAQ is initiated based on a presumptive diagnosis of non-infectious diarrhea, then there is a risk that patients with infectious etiologies will not receive the appropriate treatments, and their disease may worsen. Before starting FULY…
Adverse Reactions
- 6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. A total of 696 HIV-positive patie…
Drug Interactions
- 7.1 Drug Interaction Potential
In vitro studies have shown that crofelemer has the potential to inhibit cytochrome P450 isoenzyme 3A and transporters MRP2 and OATP1A2 at concentrations expected in the gut. Due to the minimal absorption of crofelemer, it is unlikely to inhibit cytochrome P450 isoenzymes 1A2, … - 7.2 Nelfinavir, Zidovudine, and Lamivudine
FULYZAQ administration did not have a clinically relevant interaction with nelfinavir, zidovudine, or lamivudine in a drug-drug interaction trial.
8 Use in Specific Populations
- 8.1 Pregnancy
Pregnancy Category C Reproduction studies performed with crofelemer in rats at oral doses up to 177 times the recommended daily human dose of 4.2 mg/kg revealed no evidence of impaired fertility or harm to the fetus. In pregnant rabbits, crofelemer at an oral dose of about 96 times th… - 8.3 Nursing Mothers
It is not known whether crofelemer is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for adverse reactions in nursing infants from FULYZAQ, a decision should be made whether to discontinue nursing or to discontinue the drug, …
11 Description
- FULYZAQ (crofelemer) delayed-release tablets is an anti-diarrheal, enteric-coated drug product for oral administration. It contains 125 mg of crofelemer, a botanical drug substance that is derived from the red latex of Croton lechleriMüll. Arg. Crofelemer is an oligomeric proanthocyanidin mixture primarily composed of (+)–catechin, (–)–epicatechin, (+)–gallocatechin, and (–)–epigal…
Clinical Pharmacology
- 12.1 Mechanism of Action
Crofelemer is an inhibitor of both the cyclic adenosine monophosphate (cAMP)-stimulated cystic fibrosis transmembrane conductance regulator (CFTR) chloride ion (Cl¯) channel, and the calcium-activated Cl¯ channels (CaCC) at the luminal membrane of enterocytes. The CFTR Cl¯ c… - 12.2 Pharmacodynamics
Consistent with the mechanism of action of crofelemer (i.e., inhibition of CFTR and CaCC in the GI lumen), data suggest stool chloride concentrations decreased in patients treated with FULYZAQ (500 mg four times daily) (n=25) for four days relative to placebo (n=24); stool chloride concentr…
Nonclinical Toxicology
- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenesis Long-term studies in animals have not been performed to evaluate the carcinogenic potential of crofelemer. Mutagenesis Crofelemer was negative in the bacterial reverse mutation assay, chromosomal aberration assay, and rat bone marrow micronucleus ass…